A kind of dehydrogenated Peganum harmala alkaloid derivative, preparation method and application thereof
By modifying the dehydrogenated larch, the introduction of phenolboric acid and alkyl chains into its structure, a new anti-tumor drug is formed. This drug can achieve selective effects on tumor cells by targeting sialic acid, solving existing drugs The problem of large toxic side effects and low treatment index have achieved efficient and low toxic anti-tumor effects.
Patent Information
- Application Number
- CN202310504156.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-06
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2043-05-06
Smart Images

Figure CN116514858B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of compound synthesis, in particular to a derivative based on a β-carboline alkaloid prototype, its synthesis and application, and belongs to the technical field of pharmaceutical preparation. Background Art
[0002] At present, cancer is still the main cause of death in humans except for the elderly, but most of the existing tumor therapeutic drugs still have large toxic side effects and low therapeutic index, so there is an urgent need for the development of high-efficiency and low-toxic tumor targeted drugs. Harmine (HM) is a tricyclic β-carboline alkaloid extracted from the seeds of Peganum harmala, a plant of the Tribulus terrestris family. It has multiple pharmacological effects such as anti-inflammatory, antibacterial, antiparasitic, antidiabetic, and broad-spectrum antitumor effects. As a potential antitumor drug, its antitumor activity has attracted much attention from scholars at home and abroad in recent years. Due to its certain neurotoxicity, its application in antitumor is limited. By rationally modifying its chemical structure, its toxic side effects can be effectively reduced or even eliminated, and its antitumor effect can be fully exerted or enhanced.
[0003] Phenylboronic acid can form a reversible cyclic boron ester structure with polyols, and is often used as a ligand to bind to polysaccharide molecules containing 1,2-diols, 1,3-diols or polyols. In the weakly acidic microenvironment of tumors, non-free phenylboronic acid cannot form a stable structure with other sugar groups, but can specifically bind to sialic acid to form a stable complex. Sialic acid is a general term for a class of sugar residues containing 9 carbon atoms and a pyranose structure. It belongs to a class of neuraminic acid derivatives and is often located at the end of the polysaccharide chain. A large number of studies have reported that sialic acid expression in tumor tissues is significantly higher than that in normal tissues. The high distribution of sialic acid helps to reduce the adhesion between tumor cells and create favorable conditions for tumor metastasis, which is one of the reasons for the high tumor metastasis rate. Based on the above characteristics, targeted drugs modified with phenylboronic acid as a ligand are designed with sialic acid as the targeting site. By identifying the highly distributed sialic acid on the tumor surface, targeted selection of tumor cells is achieved, improving drug delivery and action efficiency. Summary of the invention
[0004] The purpose of the present invention is to provide a new structure dehydrogenated harmine derivative with simple synthesis process, low production cost, high yield, high purity of the obtained product and broad anti-tumor effect, a preparation method and application thereof.
[0005] The technical solution used to achieve the purpose of the present invention is to provide a dehydrogenated harmine derivative compound, which has the structural formula:
[0006] .
[0007] The method for preparing a dehydrogenated harmine derivative compound described in the technical solution of the present invention comprises the following steps:
[0008] (1) Based on the molar mass ratio, 1 part of dehydrogenated harmaline is activated with 5 to 10 parts of sodium hydride in an anhydrous solvent, and then added to 2 to 10 parts of 4-bromobutylphthalimide. The mixture is reacted for 2 to 4 hours at room temperature under nitrogen protection, and then diluted and extracted with an organic solvent. The mixture is quenched, washed, dried, filtered, and concentrated to obtain a concentrated solution. A 50 to 300-fold volume of a low-polarity organic solvent, petroleum ether, is added to the concentrated solution, and the solution is allowed to stand for precipitation and then filtered to obtain the first intermediate N9-(4-(1,3-dioxoisoindolin-2-yl)butyl)dehydrogenated harmaline.
[0009] (2) Under nitrogen protection, dissolve 1 part of the first intermediate in an anhydrous reagent, heat under reflux and stir, add 10 to 50 parts of hydrazine hydrate to remove the phthaloyl group, cool after the reaction is complete, filter and concentrate to obtain a concentrated solution, add 20 to 200 times the volume of the concentrated solution of low-polarity organic solvent dichloromethane, let stand, and precipitate to obtain the second intermediate N9-(4-aminobutyl)dehydro-harmaline;
[0010] (3) Based on the molar mass ratio, 1.2 to 5 parts of 4-carboxyphenylboronic acid, 1.2 to 5 parts of (1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) and 1.2 to 5 parts of N-hydroxysuccinimide (NHS) are treated in an ice bath to activate the carboxyl group for 1 to 3 hours, and then 1 part of the second intermediate is added. The reaction is carried out at room temperature in the dark for more than 24 hours, and the reaction solution is purified by column chromatography to obtain a dehydrogenated harmine derivative compound.
[0011] In the above preparation method, in step (1), dichloromethane is used as the extractant of the reaction solution, quenched with saturated ammonium chloride, washed with saturated brine, and then a mixed solvent method is used to precipitate the first intermediate using a volume ratio of dichloromethane to petroleum ether of 1:50 to 300.
[0012] The technical solution of the present invention also includes an application of a dehydrogenated harmine derivative, wherein the prepared dehydrogenated harmine derivative is made into a pharmaceutical preparation for targeted cancer treatment.
[0013] The present invention provides a dehydrogenated harmine derivative, which utilizes the carboxyl group on carboxyphenylboronic acid to react with the amino-derivatized dehydrogenated harmine to undergo an amidation reaction, thereby modifying the dehydrogenated harmine with phenylboronic acid; 9 An alkyl chain with a carbon chain length of 4 is introduced at the alkyl chain to effectively improve the anti-tumor activity of the compound; then the targeting group phenylboronic acid is introduced on the alkyl chain through an amidation reaction. Phenylboronic acid can achieve targeted selection of tumor cells by recognizing the highly distributed sialic acid on the surface of tumor cells, thereby improving drug delivery and action efficiency; at the same time, the aromatic lipid structure of phenylboronic acid can also effectively enhance the anti-tumor activity of the compound.
[0014] Compared with the prior art, the technical solution of the present invention has the following beneficial effects:
[0015] 1. After the dehydrogenated echinopsine is modified with phenylboronic acid, the drug can be targeted and enriched in tumor tissues, thereby improving the therapeutic effect of the drug. After interacting with a variety of tumor cells, the results showed that the derivative retained and enhanced the proliferation inhibition effect on a variety of tumor cells.
[0016] 2. The molecular weight of the dehydrogenated harmine derivative compound obtained by the present invention is increased, the polarity is enhanced, and the neurotoxicity is weakened. The acute toxicity preliminary experiment on mice shows that after the modification of dehydrogenated harmine, the toxic reaction is greatly reduced, and no obvious toxic reaction occurs when the oral administration dose reaches 20g / kg, which is within the safety range.
[0017] 3. The dehydrogenated harmine derivative compound provided by the present invention has low production cost and simple synthesis process. The product obtained by recrystallization by multiple mixed solvent method has high purity and is easy to realize industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 , 2 The nuclear magnetic resonance ( 1 H-NMR, 13 C-NMR) spectrum;
[0019] Figure 3 A mass spectrum of a dehydrogenated harmine derivative compound provided in an embodiment of the present invention;
[0020] Figure 4 , 5 , 6, and 7 are comparative graphs of the proliferation inhibition results of the dehydrogenated harmine derivative compound (HP) and the raw material drug dehydrogenated harmine (HM) provided in the embodiments of the present invention on human lung cancer A549 cells, human liver cancer HepG2 cells, human cervical cancer Hela cells, and human breast cancer M231 cells. Implementation
[0021] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and embodiments. Example 1
[0022] This embodiment provides a dehydrogenated harmine derivative compound, and the reaction formula thereof is as follows:
[0023] .
[0024] The specific preparation method comprises the following steps:
[0025] (1) Dehydrogenated echinopsine (a), sodium hydride and a stirrer were placed in a two-necked flask, evacuated, filled with nitrogen for protection, anhydrous DMF was injected as solvent, stirred at room temperature for 1 h, the H at the N9 position of dehydrogenated echinopsine was fully activated, stirring was continued, and 4-bromobutylphthalimide (DMF as solvent) was slowly injected, stirring was continued for 2 h, and the reaction was monitored by thin layer chromatography (dichloromethane: methanol = 10:1). After the reaction was completed, the reaction solution was transferred to a separatory funnel, diluted with dichloromethane, quenched with saturated ammonium chloride solution, washed with saturated brine 3 times, the organic phase was concentrated by rotary evaporation, petroleum ether was added, and allowed to stand overnight, filtered, and the first intermediate (b) was obtained, with a molecular weight of 413 g / mol and a yield of about 90%. In the reaction, the molar ratio of dehydrogenated echinopsine, sodium hydride, and 4-bromobutylphthalimide was 1:10:2.
[0026] (2) The first intermediate obtained in step (1) and the stirring bar are put into a two-necked bottle, loaded into an oil bath pot and a condensation circulation device, evacuated, filled with nitrogen protection, injected with anhydrous ethanol, heated to 78°C, fully stirred to dissolve, and then slowly injected with 85% hydrazine hydrate solution, maintained at 78°C for 4 h, and the reaction was monitored by silica gel thin layer chromatography (TLC) (dichloromethane: methanol: formic acid = 10:1:0.1). The reaction solution was filtered, and after the reaction solution was cooled to room temperature, dichloromethane was added and mixed, and the mixture was allowed to stand in an ice bath overnight to precipitate the second intermediate (c), filter, and evaporate naturally. The yield was about 85%. The molar ratio of the second intermediate to hydrazine hydrate in the reaction was 1:10.
[0027] (3) 4-carboxyphenylboronic acid was dissolved in anhydrous DMF, mixed with activating agents EDC and NHS in an ice bath and stirred for 1.5 h, and the DMF mixed solution of the second intermediate was slowly added dropwise, and reacted at room temperature in the dark for 24-48 h. After post-treatment, the reaction was separated and purified by column chromatography to obtain the final product (d) (hereinafter abbreviated as HM-N-PBA, HP). The molecular weight of HM-N-PBA is 431 g / mol; before mixing, the molar ratio of 4-carboxyphenylboronic acid, EDC, NHS and the second intermediate was 1.2:1.2:1.2:1.
[0028] The compound obtained in this example was characterized and the performance of the product was measured.
[0029] 10 mg of the product was dissolved in 600 μL of deuterated DMSO and detected by 600 MHz nuclear magnetic resonance.
[0030] See attached Figure 1 ,for 1 H-NMR spectrum: 1H NMR (600 MHz, DMSO-d6) δ 8.47 (t, J = 5.8Hz, 1H), 8.20 (s, 1H), 8.16 (d, J = 5.2 Hz, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.88 (d, J = 5.2 Hz, 1H), 7.86 – 7.79 (m, 2H), 7.75 (d, J = 8.1 Hz, 2H), 7.21(d, J = 2.1 Hz, 1H), 6.86 (dd, J = 8.6, 2.1 Hz, 1H), 4.58 (t, J = 7.7 Hz, 2H), 3.87 (s, 3H), 3.17 (s, 1H), 2.93 (s, 3H), 1.81 – 1.76 (m, 2H), 1.64 (p,J = 6.9 Hz, 2H).;
[0031] See attached Figure 2 ,for 13 C-NMR spectrum: 13 C NMR (151 MHz, DMSO-d6) δ 166.88, 161.05,143.27, 140.80, 137.89, 136.35, 134.91, 134.33, 129.03, 126.42, 122.86,114.57, 112.74, 109.66, 94.12, 56.01, 44.28, 39.08, 28.16, 26.87, 23.29.;
[0032] See attached Figure 3 , is the mass spectrum of the dehydrogenated harmine derivative compound provided in this embodiment;
[0033] Depend on Figure 1 , 2 The results of 3 and 4 indicate that the dehydrogenated harmine derivative compound product with the structure described in this example was successfully synthesized.
[0034] The dehydrogenated harmaline derivative compound prepared in this example was investigated for its in vitro anti-tumor effect.
[0035] Haremidine has a wide range of antitumor activity, but its clinical effect is greatly limited due to its high neurotoxicity. Appropriate structural modification of harmine can effectively enhance its antitumor activity and reduce neurotoxicity. In order to investigate the antitumor activity of the new harmine derivative, CCK-8 reagent was used for cell proliferation inhibition experiment. The IC50 The experimental scheme is as follows:
[0036] (1) Preparation of culture medium: Add 50 mL FBS and 5 mL double antibody (penicillin and streptomycin) to 500 mL DMEM culture medium, mix evenly, and store in a 4°C refrigerator.
[0037] (2) Preparation of PBS solution: Weigh 0.72 g of disodium hydrogen phosphate (Na2HPO4·12H2O), 0.12 g of potassium dihydrogen phosphate (KH2PO4), and 4 g of sodium chloride (NaCl) on a balance and dissolve them in 400 mL of sterile distilled water. Add hydrochloric acid dropwise to adjust the pH value of the solution to 7.4. Transfer the solution to a 500 mL volumetric flask and continue to add distilled water to make up to volume to obtain 500 mL of 0.01 M phosphate buffer.
[0038] (3) Cell culture and passaging: According to the characteristics of the cells, human liver cancer HepG2 cells, lung cancer human alveolar basal epithelial A549 cells, human breast cancer MDA-MB-231 cells and human cervical cancer Hela cells were cultured in DMEM medium containing serum and double antibodies and placed in an incubator at 37°C and 5% CO2. The culture medium was changed every 1-2 days, and the cells were passaged after the monolayer covered the culture dish: ① Digestion: Aspirate the original culture medium and add 2 mL PBS to the culture dish for rinsing; discard it and add 2 mL trypsin to digest for 2-7 minutes to separate the cells into single cells; ② Centrifugation: Add the old culture medium to terminate the digestion, transfer to a 15 mL centrifuge tube and centrifuge at 1500 rpm for 5 minutes; ③ Discard the supernatant, add 1 mL fresh culture medium and blow evenly, making sure the tip of the gun is below the liquid surface to avoid blowing out bubbles; ④ Evenly distribute the above cell suspension into 3 culture dishes, and then add 10 mL Fresh culture medium, cross-shake gently to disperse the cells evenly, observe under the microscope that the cells are individually dispersed and rounded, with distinct morphology and clear outlines, and finally place them in a CO2 incubator for further culture. After three times, perform CCK-8 experiments.
[0039] (4) Plate laying: Take a 96-well plate and add 200 mL of PBS solution to the outermost part to prevent the liquid in the effective wells of the plate from evaporating. Take tumor cells in the logarithmic growth phase and adjust the cell suspension to the corresponding cell density. 4 200 mL / well were inoculated into 96-well plates; the plates were placed in an incubator at 37°C and 5% CO2 for 24 h until the cells were stable and completely attached to the plate.
[0040] (5) Preparation of compound stock solution: Accurately weigh the target product and dissolve it in 1 ml DMSO solution to prepare a 100 mmol / L stock solution. Filter and divide the solution into aliquots, label and seal them in a refrigerator at 4°C.
[0041] (6) Experimental grouping: set up three control groups (complete blank group: containing only culture medium; experimental blank group: containing cells and culture medium; negative control group: culture medium containing 0.1% DMSO) and six concentration gradient working solutions (50 mM, 40 mM, 30 mM, 20 mM, 10 mM, 5 mM), with 5 parallel wells in each group; after adding the drugs, mark the wells and place them in the incubator for 48 hours, and observe the cell growth every 8 to 10 hours.
[0042] (7) Add CCK-8: Use a pipette to discard the original drug-containing culture medium in the 96-well plate, add 100 μL of new culture medium, add 10 μL of CCK-8 in a dark environment, shake the plate gently for 5 times, and place it in the incubator to continue incubation for 1 hour.
[0043] (8) Detection: After taking out, shake the 96-well plate in parallel, place it in an ELISA reader, and detect the absorbance of each well at a wavelength of 450 nm.
[0044] (9) Calculation of cell proliferation inhibition rate and IC 50 Value: IC 50 The value is the drug concentration corresponding to 50% inhibition rate.
[0045] (10) The experimental results are shown in the attached Figure 4 , 5 , 6 and 7.
[0046] Figure 4 A comparison chart of the inhibition results of the dehydrogenated harmine derivative compound (HP) and the raw material drug dehydrogenated harmine (HM) on the proliferation of human lung cancer alveolar basal epithelial A549 cells provided in this example; Figure 5 This is a comparison of the results of HP and HM inhibiting the proliferation of human liver cancer HepG2 cells; Figure 6 This is a comparison of the results of HP and HM inhibiting the proliferation of human cervical cancer Hela cells; Figure 7 This is a comparison chart of the proliferation inhibition results of HP and HM on human breast cancer MDA-MB-231 cells.
[0047] The experimental results show that the dehydrogenated echinopsine derivative provided in this embodiment retains and effectively increases the broad-spectrum anti-tumor effect of dehydrogenated echinopsine, and preliminary acute toxicity experiments show that its neurotoxicity is greatly weakened. The new compound of the present invention has a good toxicity reduction and synergistic effect compared with the original compound, and can be better suitable for anti-tumor drug application.
[0048] The present invention connects the target molecule phenylboronic acid to make the dehydrogenated harmine derivative more selective to tumor cells, and because its molecular weight and molecular polarity are relatively increased, the toxicity to nerves will be effectively weakened. In order to enhance its water solubility, it is considered to further prepare the drug into inclusion compounds or nanoparticles for development as a new type of anticancer drug or to combine it with other conventional antitumor drugs, such as cisplatin, fluorouracil, camptothecin, doxorubicin, etc., which will have great potential and application prospects.
Claims
1. A dehydrogenated harmine derivative compound, characterized in that Its structural formula is: 。 2. The use of a dehydrogenated harmine derivative compound according to claim 1, characterized in that: Harmine The derivatives are made into pharmaceutical preparations for targeted cancer therapy.
Citation Information
Patent Citations
Yageine derivates having antineoplastic activity
CN101328175A
Harmine derivative anti-tumor prodrug with target characteristic
CN102977096A
